Background
infection, sCAP, inflammation
INFLAMMATION, RECRUITMENT, INFECTION, HYPOGAMMAGLOBULINEMIA, COMMUNITY-ACQUIRED PNEUMONIA, INFLAMMATORY RESPONSE
Severe community-acquired pneumonia (sCAP) still carries high mortality and morbidity despite adequate antibiotic therapy [The host immune response includes recruitment of neutrophils to the site of infection which, together with immunoglobulins (Ig) and the complement system, supports phagocytosis of pathogens and removal of damaged host cell constituents [Hypogammaglobulinemia can occur in sCAP [Immunoglobulin-based therapy can both augment the host’s anti-microbial activity and modify the dysregulated immune response [The hypothesis underpinning this additional post hoc analysis of the phase II CIGMA trial was that the observed survival benefit with trimodulin results from beneficially modulating the dysregulated inflammatory response in sCAP patients. Our aim was to evaluate the pharmacodynamic effects of trimodulin on different cellular and soluble inflammation markers associated with sCAP. The impact of trimodulin on mortality in patient subgroups with different baseline levels of dysregulated inflammatory markers was also assessed.